Upregulated expression of a unique gene by hepatitis B x antigen promotes hepatocellular growth and tumorigenesis

Neoplasia

Volumn 5, Issue 3, 2003, Pages 229-244

  Lian, Zhaorui ^a   Liu, Jie ^a   Li, Li ^a,b   Li, Xianxing ^b   Satiroglu Tufan, N Lale ^a   Clayton, Marcy ^a   Wu, Meng Chao ^c   Wang, Hong Yang ^c   Arbuthnot, Patrick ^d   Kew, Michael ^d   Feitelson, Mark A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Chengzheng Hospital   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cell cycle; Hepatitis B virushepatitis B x antigen; Hepatocellular carcinoma; Oncogene

Indexed keywords

HEPATITIS B ANTIGEN; HEPATITIS B X ANTIGEN; MESSENGER RNA; PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL ISOLATION; CELL STRAIN HEPG2; CLINICAL ARTICLE; GENE CONTROL; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA ISOLATION; SCID MOUSE; STAINING;

EID: 10744227014     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80055-6     Document Type: Article

References (55)

1. Tiollais P, Pourcel C, and Dejean A (1985). The hepatitis B virus. Nature 317, 489-95.
2. Beasley RP, and Hwang LY (1984). Epidemiology of hepatocellular carcinoma. In Viral Hepatitis and Liver Disease. GN Vyas, JL Dienstag, and JH Hoofnagle (Eds.). Grune and Stratton, New York, pp. 209-24.
3. Szmuness W (1978). Hepatocellular carcinoma and hepatitis B virus: evidence for a causal association. Prog Med Virol 24, 40-69.
4. Paterlini P, Poussin K, Kew M, Franco D, and Brechot C (1995). Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 21, 313-21.
5. Diamantis ID, McGandy CE, Chen T-J, Liaw Y-F, Gudat F, and Bianchi L (1992). Hepatitis B x gene expression in hepatocellular carcinoma. J Hepatol 15, 400-3.
6. Wang W, London WT, Lega L, and Feitelson MA (1991). HBxAg in the liver from carrier patients with chronic hepatitis and cirrhosis. Hepatology 14, 29-37.
7. Wang W, London WT, and Feitelson MA (1991). Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res 51, 4971-7.
8. Feitelson MA, Lega L, Duan LX, and Clayton M (1993). Characteristics of woodchuck hepatitis X antigen in the livers and sera from chronically infected animals. J Hepatol 17 (Suppl 3), S24-34.
9. Jin YM, Yun C, Park C, Wang HJ, and Cho H (2001). Expression of hepatitis B virus X protein is closely correlated with the high periportal inflammatory activity of liver diseases. J Viral Hepatitis 8, 322-30.
10. Koike K, Shirakata Y, Yaginuma K, Arii M, Takada S, Nakamura I, Hayashi Y, Kawada M, and Kobayashi M (1989). Oncogenic potential of HBV. Mol Biol Med 6, 151-60.
11. Hohne M, Schaefer S, Seifer M, Feitelson MA, Paul D, and Gerlich WG (1990). Malignant transformation of immortalized hepatocytes by HBV DNA. EMBO J 9, 1137-45.
12. Seifer M, Hohne M, Schaefer S, and Gerlich WH (1991). In vitro tumorigenicity of hepatitis B virus DNA and HBx protein. J Hepatol 13 (Suppl 4), 61-5.
13. Kim CM, Koike K, Saito I, Miyamura T, and Jay G (1991). HBx gene of HBV induces liver cancer in transgenic mice. Nature 351, 317-20.
14. Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, Miyamura T, and Kurokawa K (1994). High level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 19, 810-9.
15. Ueda H, Ullrich SJ, Ngo L, Feitelson MA, and Jay G (1995). Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 9, 41-7.
16. Henkler F, and Koshy, R (1996). Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. J Viral Hepatitis 3, 109-21.
17. Rossner MT (1992). Hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol 36, 101-17.
18. Autunovic J, Lemieux N, and Cromlish JA (1993). The 17 kDa HBx protein encoded by hepatitis B virus interacts with the activation domains of Oct-1, and functions as a coactivator in the activation and repression of a human U6 promoter. Cell Mol Biol Res 39, 463-82.
19. Maguire HF, Hoeffler JP, and Siddiqui A (1991). HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 52, 842-4.
20. Qadri K, Maguire HF, and Siddiqui A (1995). Hepatitis B virus transactivator protein X interacts with the TATA-binding protein. Proc Natl Acad Sci USA 92, 1003-7.
21. Cheong JH, Yi M, Lin Y, and Murakami S (1995). Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J 14, 142-50.
22. Haviv I, Vaizel D, and Shaul Y (1995). The X protein of hepatitis B virus coactivates potent activation domains. Mol Cell Biol 15, 1079-85.
23. Haviv I, Vaizet D, and Shaul Y (1996). pX, the HBV-encoded coactivator, interacts with components of the transcription machinery and stimulates transcription in a TAF-independent manner. EMBO J 15, 3413-20.
24. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu J, and Harris CC (1994). Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity and association with ERCC3. Proc Natl Acad Sci USA 91, 2230-4.
25. Sun BS, Zhu X, Clayton MM, Pan J, and Feitelson MA (1988). Identification and preliminary characterization of a protein involved in cellular senescence which binds to hepatitis B virus X antigen. Hepatology 27, 228-39.
26. Feitelson MA, Reis H, Pan J, Lian Z, Fang J, Liu J, Zhu X, Zhu M, and Sun B (1999). Abrogation of negative growth regulatory pathways by hepatitis B virus encoded X antigen in the development of hepatocellular carcinoma. In Normal and Malignant Liver Cell Growth: FALK Workshop. WE Fleig (Ed.). Kluwer Academic Publishing, Lancaster, UK, pp. 156-70.
27. Lan Z, Pan J, Liu J, Zhu M, Arbuthnot P, Kew MC, and Feitelson MA (1999). The translation initiation factor, SUI1, may be a target of Hepatitis B x antigen in hepatocarcinogenesis. Oncogene 18, 1677-87.
28. Lucito R, and Schneider RJ (1992). Hepatitis B virus X protein activates transcription factor NF-κB without a requirement for protein kinase C. J Virol 66, 983-91.
29. Chirillo P, Falco M, Puri PL, Artini M, Balsano C, Levrero M, and Natoli G (1996). Hepatitis B virus pX activates NF-κB dependent transcription through a raf-independent pathway. J Virol 70, 641-6.
30. Seto E, Mitchell PJ, and Yen TSB (1990). Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature 344, 72-4.
31. Benn J, and Schneider RJ (1994). Hepatitis B virus HBx protein activates ras-GTP complex formation and establishes a ras, raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 91, 10350-4.
32. Nijhara R, Jana SS, Goswami SK, Rana A, Majumdar SS, Kumar V, and Sarkar DP (2001). Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo. J Virol 75, 10348-58.
33. Shih WL, Kuo ML, Chuang SE, Cheng AL, and Doong SL (2000). Hepatitis B virus X protein inhibits transforming growth factor-beta-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J Biol Chem 275, 25858-64.
34. Lian Z, Liu J, Pan J, Tufan NLS, Zhu M, Arbuthnot P, Kew M, Clayton MM, and Feitelson MA (2001). A cellular gene up-regulated by hepatitis B virus encoded X antigen promotes hepatocellular growth and survival. Hepatology 34, 146-57.
35. Benson DA, Boguski MS, Lopman DJ, and Ostell J (1997). GenBank. Nucleic Acids Res 25, 1-6.
36. Feitelson MA, Millman I, Duncan GD, and Blumberg BS (1988). Presence of antibodies to the polymerase gene product(s) of hepatitis B and woodchuck hepatitis virus in natural and experimental infections. J Med Virol 24, 121-36.
37. Feitelson MA, and Clayton MM (1990). X antigen polypeptides in the sera of hepatitis B virus infected patients. Virology 177, 367-71.
38. Feitelson MA, Clayton MM, and Blumberg BS (1990). X antigen/ antibody markers in hepadnavirus infection: presence and significance of hepadnavirus X gene product(s) in serum. Gastroenterology 98, 1071-8.
39. Sells MA, Chen ML, and Acs G (1987). Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 84, 1005-9.
40. Gottlob K, Fulco M, Levrero M, and Greessmann A (1998). The hepatitis B virus HBx protein inhibits caspase 3 activity. J Biol Chem 273, 33347-53.
41. Feitelson MA, and Duan XL (1997). Hepatitis B virus x antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol 150, 1141-57.
42. Tufan NLS, Lian Z, Liu J, Pan J, Arbuthnot P, Kew M, Clayton MM, and Feitelson MA (2002). Hepatitis B x antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia 4, 355-68.
43. Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, and Sasaki K (1999). Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 29, 1858-62.
44. Feitelson MA, Sun B, Tufan NL, Liu J, Pan J, and Lian Z (2002). Genetic mechanisms of hepatocarcinogenesis. Oncogene 21, 2593-604.
45. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkanen M, Varis A, Wasenius VM, Wolf M, and Zhu Y (1999). DNA copy number losses in human neoplasms. Am J Pathol 155, 683-94.
46. Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, Pham TA, Dillard-Telm L, Tsai SP, Stephan JP, Stinson J, Stewart T, and French DM (2002). A mouse model of hepatocellular carcinoma. Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160, 2295-307.
47. Nishiu J, Tanaka T, and Nakamura Y (1998). Identification of a novel gene (ECM2) encoding a putative extracellular matrix protein expressed predominantly in adipose and specific tissues and its chromosomal localization to 9q22.3. Genomics 52, 378-81.
48. Drickamer K (1999). C-type lectin-like domains. Curr Opin Struct Biol 9, 585-90.
49. Tomasetto C, Masson R, Linares JL, Wendling C, Lefebvre O, Chenard MP, and Rio MC (2000). pS2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. Gastroenterology 118, 70-80.
50. Christian S, Ahorn H, Koehler A, Eisenhaber F, Rodi HP, Garin-chesa P, Park JE, Rettig WJ, and Lenter MC (2001). Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 276, 7408-14.
51. Llera AS, Viedma F, Sanchez-Madrid F, and Tormo J (2001). Crystal structure of the C-type lectin-like domain from the human hematopoietic cell receptor CD69. J Biol Chem 276, 7312-9.
52. Olin AI, Morgelin M, Sasaki T, Timple R, Heinegard D, and Aspberg A (2001). The proteoglycans aggrecan and versican from networks with fibulin-2 through their lectin domain binding. J Biol Chem 276, 1253-61.
53. Bork P (1993). The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 327, 125-30.
54. Bouchard MJ, Wang LH, and Schneider RJ (2001). Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 294, 2376-8.
55. 2+: the clue to hepatitis B virus X protein function? Hepatology 36, 755-7.